Publication:
Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study

Simple item page
dc.contributor.authorKiremitci S.
dc.contributor.authorKochan K.
dc.contributor.authorSEVEN G.
dc.contributor.authorKeskin E. B.
dc.contributor.authorOKAY G.
dc.contributor.authorAKKOYUNLU Y.
dc.contributor.authorKoc M. M.
dc.contributor.authorSÜMBÜL B.
dc.contributor.authorŞENTÜRK H.
dc.contributor.institutionauthorKİREMİTÇİ, SERCAN
dc.contributor.institutionauthorKOÇHAN, KORAY
dc.contributor.institutionauthorSEVEN, GÜLSEREN
dc.contributor.institutionauthorOKAY, GÜLAY
dc.contributor.institutionauthorAKKOYUNLU, YASEMİN
dc.contributor.institutionauthorSÜMBÜL, BİLGE
dc.contributor.institutionauthorŞENTÜRK, HAKAN
dc.date.accessioned2024-02-22T21:50:20Z
dc.date.available2024-02-22T21:50:20Z
dc.date.issued2024-01-01
dc.description.abstractBackground/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accordance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAgnegative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36-276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of 2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-Treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-Threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated.
dc.identifier.citationKiremitci S., Kochan K., SEVEN G., Keskin E. B., OKAY G., AKKOYUNLU Y., Koc M. M., SÜMBÜL B., ŞENTÜRK H., "Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study", Turkish Journal of Gastroenterology, cilt.35, sa.1, ss.17-26, 2024
dc.identifier.doi10.5152/tjg.2024.23463
dc.identifier.endpage26
dc.identifier.issn1300-4948
dc.identifier.issue1
dc.identifier.scopus85182997711
dc.identifier.startpage17
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85182997711&origin=inward
dc.identifier.urihttps://hdl.handle.net/20.500.12645/39107
dc.identifier.volume35
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectGenel Tıp
dc.subjectGeneral Medicine
dc.subjectChronic hepatitis B
dc.subjectHBeAg-negative
dc.subjectHBsAg loss
dc.subjectlamivudine resistance
dc.subjectnucleos(t)ide analog discontinuation
dc.titleResults of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study
dc.typearticle
dspace.entity.typePublication
local.avesis.id27326add-6c47-4c32-a780-8437c12c0efb
relation.isAuthorOfPublication4145627c-024b-41dd-9df0-5e8924b91b3c
relation.isAuthorOfPublicationb76fc646-d4e6-42fc-86d4-534d33d0b6c9
relation.isAuthorOfPublicationfedf47e7-d7dd-44db-ada5-60bbaef0ae5b
relation.isAuthorOfPublication279981fb-cbc1-47b0-aba0-2735e8c96c27
relation.isAuthorOfPublicationfc9e6e5e-089f-4a24-bc0e-7003bbed7005
relation.isAuthorOfPublication51568f47-69f1-46a2-b201-e6d6161080a8
relation.isAuthorOfPublication278fcf63-3b92-4368-bff6-f140ebd9aeb3
relation.isAuthorOfPublication.latestForDiscovery4145627c-024b-41dd-9df0-5e8924b91b3c
Files
Collections
Yayınlar - Eserler